FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050227906> ?p ?o ?g. }

• W2050227906 endingPage "469" @default.
• W2050227906 startingPage "461" @default.
• W2050227906 abstract "No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Aug 2001CHEMOSENSITIZATION OF BLADDER CARCINOMA CELLS BY BCL-xL ANTISENSE OLIGONUCLEOTIDES IRINA LEBEDEVA, ANTHONY RAFFO, ROBERT RANDO, JOSHUA OJWANG, PAUL COSSUM, and C.A. STEIN IRINA LEBEDEVAIRINA LEBEDEVA More articles by this author , ANTHONY RAFFOANTHONY RAFFO More articles by this author , ROBERT RANDOROBERT RANDO More articles by this author , JOSHUA OJWANGJOSHUA OJWANG More articles by this author , PAUL COSSUMPAUL COSSUM Financial interest and/or other relationship with Aronex Pharmaceuticals. More articles by this author , and C.A. STEINC.A. STEIN More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)65964-2AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We investigated antisense inhibition of anti-apoptotic bcl-xL and bcl-2 proteins to increase chemosensitization in the T24 and 5637 bladder carcinoma cell lines. Materials and Methods: A T24 bladder carcinoma cell line stably over expressing bcl-xL protein was constructed. Apoptosis by cytotoxic agents was estimated by cell cycle analysis and Annexin V binding. To eliminate bcl-xL expression T24 and 5637 cells were treated with C5-propynylated and 2′-O-methylribo-oligonucleotides. Levels of protein and messenger RNA were measured by Western and Northern blot analysis. Cell viability after combined treatment with oligonucleotides and various cytotoxic agents was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and evaluated statistically by Student’s 2-sample t test. Results: Forced over expression of bcl-xL protein desensitized the T24 bladder carcinoma cell line to cytotoxic agents. C5-propynylated and 2′-O-methylribo-oligonucleotides down-regulated bcl-xL protein expression in the T24 and 5637 cell lines, and increased their sensitivity to cytotoxic agents. The efficiency of antisense down-regulation of bcl-xL protein expression depended on the type of delivery agent. Conclusions: Antisense down-regulation of bcl-xL protein sensitizes bladder carcinoma cells to cytotoxic agents. However, it is possible that cellular chemosensitization results from a combination of effects, including nonsequence specificity, irrelevant cleavage and effects of the carriers combined with the specific antisense effects. References 1 : Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res1995; 55: 4438. Google Scholar 2 : Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res2000; 60: 6052. Google Scholar 3 : Calcium ionophore, ionomycin inhibits growth of human bladder cancer cells both in vitro and in vivo with alteration of Bcl-2 and Bax expression levels. J Urol1999; 162: 916. Link, Google Scholar 4 : Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells. Br J Cancer1999; 79: 1651. Google Scholar 5 : Bcl-2 and p53 expressions in invasive bladder cancers. Acta Oncol1998; 37: 715. Google Scholar 6 : Bcl-2 and p53 overexpression as associated risk factors in transitional cell carcinoma of the bladder. Int Urol Nephrol1998; 30: 455. Google Scholar 7 : Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res1997; 3: 1823. Google Scholar 8 : Immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer. Finnbladder III Group. Urol Res1997; 25: 1. Google Scholar 9 : Expression of bcl-2 and bcl-X in bladder cancer. J Urol1998; 159: 1348. Link, Google Scholar 10 : Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int2000; 85: 829. Google Scholar 11 : Variable levels of bcl-2, bcl-x and bax mRNA in bladder cancer progression. Oncol Rep1998; 5: 901. Google Scholar 12 : Immunohistochemical evaluation of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 expression during bacillus Calmette-Guerin (BCG) intravesical instillation therapy for superficial bladder cancers. Urol Res1998; 26: 161. Google Scholar 13 : Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem1993; 268: 14514. Google Scholar 14 : Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science1993; 260: 1510. Google Scholar 15 : Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides. Nucleic Acids Res1998; 26: 5310. Google Scholar 16 : Is irrelevant cleavage the price of antisense efficacy?. Pharmacol Ther2000; 85: 231. Google Scholar 17 : Inhibition of Bcl-xL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli. Oncogene1999; 18: 4495. Google Scholar 18 : Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res1988; 16: 3209. Google Scholar 19 : Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem1995; 270: 2620. Google Scholar 20 : Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J Biol Chem1995; 270: 21718. Google Scholar 21 : Antisense oligonucleotides in cancer: recent advances. BioDrugs2000; 13: 195. Google Scholar 22 : Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides. Biochemistry1995; 34: 5044. Google Scholar 23 : RNase H-mediated inhibition of translation by antisense oligodeoxyribonucleotides: use of backbone modification to improve specificity. Gene1992; 121: 189. Google Scholar 24 : Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures. Nucleic Acids Res1992; 20: 763. Google Scholar 25 : Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem J1995; 312: 599. Google Scholar 26 : Destabilization of messenger RNA/complementary DNA duplexes by the elongating 80 S ribosome. J Biol Chem1986; 261: 16018. Google Scholar From the Departments of Medicine and Pharmacology, Columbia University, New York, New York, and Aronex Pharmaceuticals, The Woodlands, Texas© 2001 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byKRAUSE S, FÖRSTER Y, KRAEMER K, FUESSEL S, KOTZSCH M, SCHMIDT U, WIRTH M, MEYE A and SCHWENZER B (2018) VASCULAR ENDOTHELIAL GROWTH FACTOR ANTISENSE PRETREATMENT OF BLADDER CANCER CELLS SIGNIFICANTLY ENHANCES THE CYTOTOXICITY OF MITOMYCIN C, GEMCITABINE AND CISPLATINJournal of Urology, VOL. 174, NO. 1, (328-331), Online publication date: 1-Jul-2005. Volume 166Issue 2August 2001Page: 461-469 Advertisement Copyright & Permissions© 2001 by American Urological Association, Inc.Keywordsbladderbladder neoplasmsoligonucleotidesantisenseMetricsAuthor Information IRINA LEBEDEVA More articles by this author ANTHONY RAFFO More articles by this author ROBERT RANDO More articles by this author JOSHUA OJWANG More articles by this author PAUL COSSUM Financial interest and/or other relationship with Aronex Pharmaceuticals. More articles by this author C.A. STEIN More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2050227906 created "2016-06-24" @default.
• W2050227906 creator A5007862965 @default.
• W2050227906 creator A5017719790 @default.
• W2050227906 creator A5027059891 @default.
• W2050227906 creator A5038833981 @default.
• W2050227906 creator A5077631925 @default.
• W2050227906 creator A5083307220 @default.
• W2050227906 date "2001-08-01" @default.
• W2050227906 modified "2023-09-25" @default.
• W2050227906 title "CHEMOSENSITIZATION OF BLADDER CARCINOMA CELLS BY BCL-xL ANTISENSE OLIGONUCLEOTIDES" @default.
• W2050227906 cites W1529806421 @default.
• W2050227906 cites W1564730852 @default.
• W2050227906 cites W1906502852 @default.
• W2050227906 cites W1969818257 @default.
• W2050227906 cites W1976545417 @default.
• W2050227906 cites W1981481692 @default.
• W2050227906 cites W2006923303 @default.
• W2050227906 cites W2009413686 @default.
• W2050227906 cites W2009580295 @default.
• W2050227906 cites W2016696388 @default.
• W2050227906 cites W2032206932 @default.
• W2050227906 cites W2034353923 @default.
• W2050227906 cites W2043026175 @default.
• W2050227906 cites W2077102484 @default.
• W2050227906 cites W2077663005 @default.
• W2050227906 cites W2083527153 @default.
• W2050227906 cites W2093261928 @default.
• W2050227906 cites W2146204276 @default.
• W2050227906 cites W2148320915 @default.
• W2050227906 cites W2169223713 @default.
• W2050227906 cites W2332631121 @default.
• W2050227906 cites W50116936 @default.
• W2050227906 doi "https://doi.org/10.1016/s0022-5347(05)65964-2" @default.
• W2050227906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11458048" @default.
• W2050227906 hasPublicationYear "2001" @default.
• W2050227906 type Work @default.
• W2050227906 sameAs 2050227906 @default.
• W2050227906 citedByCount "36" @default.
• W2050227906 countsByYear W20502279062012 @default.
• W2050227906 countsByYear W20502279062013 @default.
• W2050227906 countsByYear W20502279062015 @default.
• W2050227906 countsByYear W20502279062023 @default.
• W2050227906 crossrefType "journal-article" @default.
• W2050227906 hasAuthorship W2050227906A5007862965 @default.
• W2050227906 hasAuthorship W2050227906A5017719790 @default.
• W2050227906 hasAuthorship W2050227906A5027059891 @default.
• W2050227906 hasAuthorship W2050227906A5038833981 @default.
• W2050227906 hasAuthorship W2050227906A5077631925 @default.
• W2050227906 hasAuthorship W2050227906A5083307220 @default.
• W2050227906 hasConcept C104317684 @default.
• W2050227906 hasConcept C129312508 @default.
• W2050227906 hasConcept C153911025 @default.
• W2050227906 hasConcept C190283241 @default.
• W2050227906 hasConcept C2776789625 @default.
• W2050227906 hasConcept C31573885 @default.
• W2050227906 hasConcept C502942594 @default.
• W2050227906 hasConcept C55493867 @default.
• W2050227906 hasConcept C71924100 @default.
• W2050227906 hasConcept C86803240 @default.
• W2050227906 hasConceptScore W2050227906C104317684 @default.
• W2050227906 hasConceptScore W2050227906C129312508 @default.
• W2050227906 hasConceptScore W2050227906C153911025 @default.
• W2050227906 hasConceptScore W2050227906C190283241 @default.
• W2050227906 hasConceptScore W2050227906C2776789625 @default.
• W2050227906 hasConceptScore W2050227906C31573885 @default.
• W2050227906 hasConceptScore W2050227906C502942594 @default.
• W2050227906 hasConceptScore W2050227906C55493867 @default.
• W2050227906 hasConceptScore W2050227906C71924100 @default.
• W2050227906 hasConceptScore W2050227906C86803240 @default.
• W2050227906 hasIssue "2" @default.
• W2050227906 hasLocation W20502279061 @default.
• W2050227906 hasLocation W20502279062 @default.
• W2050227906 hasOpenAccess W2050227906 @default.
• W2050227906 hasPrimaryLocation W20502279061 @default.
• W2050227906 hasRelatedWork W1844313867 @default.
• W2050227906 hasRelatedWork W1865915409 @default.
• W2050227906 hasRelatedWork W1984664613 @default.
• W2050227906 hasRelatedWork W1988517220 @default.
• W2050227906 hasRelatedWork W2003691989 @default.
• W2050227906 hasRelatedWork W2027976122 @default.
• W2050227906 hasRelatedWork W2068549450 @default.
• W2050227906 hasRelatedWork W2088139568 @default.
• W2050227906 hasRelatedWork W2142498284 @default.
• W2050227906 hasRelatedWork W237322376 @default.
• W2050227906 hasVolume "166" @default.
• W2050227906 isParatext "false" @default.
• W2050227906 isRetracted "false" @default.
• W2050227906 magId "2050227906" @default.
• W2050227906 workType "article" @default.